Florian Greten, MD

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy
Frankfurt Germany
Biographical Sketch: Prof. Dr. Florian R. Greten studied medicine in Hamburg and Vienna and obtained his medical degree from the University of Hamburg in 1998. From 1998 – 2000 he worked as an intern and resident with Prof. Dr. Guido Adler, University of Ulm, and from 2001 – 2004 as a postdoctoral fellow in Prof. Dr. Michael Karin’s Laboratory at the University of California, San Diego, U.S.A.. In 2004 he moved to the Technical University of Munich, where he established an Emmy-Noether-Research Group in 2005. In 2010, he became professor of Molecular Gastrointestinal Oncology at the Technical University Munich. Since 2013, Prof. Dr. Florian Greten holds a Chair of Tumor Biology at the Goethe-University, Frankfurt/Main, Germany, and is director of the Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt/Main.

Prof. Dr. Greten’s main research interest focuses on the tumor microenvironment and the signaling cascades that control cell-cell communication and polarization. Over the last years, his group has been specifically adressing how the inflammatory tumor microenvironment and particularly the IkB Kinase (IKK) affects cell plasticity in mouse models of colorectal cancer. They could demonstrate an essential function of classical IKKb-dependent NF-kB in tumor cell plasticity during tumor initiation as well as tumor progression (Schwitalla et al., Cell, 2013 and Cancer Cell, 2013).

Prof. Dr. Greten received several awards and honors, amongst them the Johann-Georg-Zimmermann Award for Cancer Research, the Dr. Emil Salzer Award for Cancer Research of the German Cancer Research Center, the AIO Scientific Award of the German Cancer Society and the German Cancer Award.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.

I will recuse myself from planning activity content in which I have a conflict of interest.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 06/25/2015 by Florian Greten

Papers:
Inflammation and Stem Cell Plasticity in Colon Cancer

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.
	I will recuse myself from planning activity content in which I have a conflict of interest.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".